FOXA1 Protein Expression in ER+ and ER− Breast Cancer in Relation to Parity and Breastfeeding in Black and White Women

Abstract
Background: Forkhead box protein A1 (FOXA1) promotes luminal differentiation, and hypermethylation of the gene can be a mechanism of developing estrogen receptor-negative (ER-) breast cancer. We examined FOXA1 in breast tumor and adjacent normal tissue in relation to reproductive factors, particularly higher parity and no breastfeeding, that are associated with ER- tumors. Methods: We performed immunohistochemistry for FOXA1 in breast tumors (n=1,329) and adjacent-normal tissues (n=298) in the Women's Circle of Health Study (949 Blacks and 380 Whites). Protein expression levels were summarized by histology (H) scores. Generalized linear models were used to assess FOXA1 protein expression in relation to reproductive factors by ER status. Results: ER+ vs. ER- tumors had higher FOXA1 protein expression (P<0.001). FOXA1 expression was higher in tumor versus paired adjacent-normal tissue in women with ER+ or non-triple-negative cancer (both P<0.001), but not in those with ER- or triple-negative cancer. Higher number of births (1, 2, and 3+) was associated with lower FOXA1 protein expression in ER+ tumors (differences in H score, or β= -8.5, 95% CI= -15.1 to -2.0), particularly among parous women who never breastfed (β= -10.4, -19.7 to -1.0), but not among those who breastfed (β = -7.5, 95% CI= -16.9 ¬to¬¬¬ 1.8). The associations for ER- tumors were similar, although they were not statistically significant. Conclusions: In this tumor-based study, higher parity was associated with lower FOXA1 expression in ER+ tumors, and breastfeeding may ameliorate the influence. Impact: These findings contribute to our understanding of FOXA1 methylation and breast cancer etiology.
Funding Information
  • U.S. Army Medical Research and Materiel Command (DAMD-17-01-1-0334)
  • NCI (R01 CA100598)
  • NCI (P01 CA151135)
  • NCI (R01 CA185623)
  • NCI (R01CA133264)
  • NCI (R01 CA225947)
  • NCI (K07 CA201334)
  • Roswell Park Comprehensive Cancer Center (P30 CA016056)
  • Rutgers Cancer Institute of New Jersey (P30 CA072720)
  • NCI (HHSN261201300021I, N01-PC-2013-00021)
  • National Program of Cancer Registries Centers for Disease Control and Prevention (NU5U58DP006279-02-00)